IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety

Barbara Grube, Udo Bongartz, Felix Alt, Barbara Grube, Udo Bongartz, Felix Alt

Abstract

The individual ingredients in IQP-VV-102 have demonstrated promising effects in reducing sugar and starch digestion, which potentially leads to weight loss. The trial objective was to evaluate the safety and efficacy of IQP-VV-102 in reducing body weight in overweight and obese subjects. 120 overweight and obese individuals aged 18 to 60 years were randomly assigned to 2 treatment arms (IQP-VV-102 and placebo). The trial was conducted in 2 study centres in Berlin, Germany. The primary efficacy analysis was conducted on 117 subjects (IQP-VV-102: N = 54; placebo: N = 59), comparing the weight loss effect at baseline and 12 weeks after randomization. There was a statistically significant reduction in mean body weight of 3.29 kg (SD 2.30) in the IQP-VV-102 group compared to 0.83 kg (SD 2.00) in the placebo group (p < 0.001). There were no serious or product-related adverse events that were reported over the combined period of 14 weeks. The findings suggested that IQP-VV-102 is effective and safe in body weight reduction in overweight and obese individuals in the short term. The study is registered under clinicaltrials.gov as NCT01681069.

Figures

Figure 1
Figure 1
Study design and disposition of subjects.
Figure 2
Figure 2
Body weight reduction over time (error bars represent SEM).

References

    1. World Health Organization. Obesity: Situations and Trends. Geneva, Switzerland: World Health Organization; 2014.
    1. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md, USA: National Institutes of Health; 1998. (NIH Publication no. 98-4083).
    1. Hamman R. F., Wing R. R., Edelstein S. L., et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–2107. doi: 10.2337/dc06-0560.
    1. Popkin B. M., Paeratakul S., Zhai F., Keyou G. A review of dietary and environmental correlates of obesity with emphasis on developing countries. Obesity Research. 1995;3:145S–153S.
    1. Wright J. D., Kennedy-Stephenson J., Wang C. Y., et al. Trends in intake of energy and macronutrients—United States, 1971–2000. Morbidity and Mortality Weekly Report. 2004;53:80–82.
    1. Wing R. R., Hill J. O. Successful weight loss maintenance. Annual Review of Nutrition. 2001;21:323–341. doi: 10.1146/annurev.nutr.21.1.323.
    1. Seri K., Sanai K., Matsuo N., Kawakubo K., Xue C., Inoue S. L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Metabolism: Clinical and Experimental. 1996;45(11):1368–1374. doi: 10.1016/s0026-0495(96)90117-1.
    1. Krog-Mikkelsen I., Hels O., Tetens I., Holst J. J., Andersen J. R., Bukhave K. The effects of L-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans. The American Journal of Clinical Nutrition. 2011;94(2):472–478. doi: 10.3945/ajcn.111.014225.
    1. Shibanuma K., Degawa Y., Houda K. Determination of the transient period of the EIS complex and investigation of the suppression of blood glucose levels by L-arabinose in healthy adults. European Journal of Nutrition. 2011;50(6):447–453. doi: 10.1007/s00394-010-0154-3.
    1. Flint H. J., Duncan S. H., Scott K. P., Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. Environmental Microbiology. 2007;9(5):1101–1111. doi: 10.1111/j.1462-2920.2007.01281.x.
    1. Osaki S., Kimura T., Sugimoto T., Hizukuri S., Iritani N. L-arabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats. The Journal of Nutrition. 2001;131(3):796–799.
    1. Gonçalves R., Mateus N., de Freitas V. Inhibition of α-amylase activity by condensed tannins. Food Chemistry. 2011;125(2):665–672. doi: 10.1016/j.foodchem.2010.09.061.
    1. Institute of Medicine. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients) Washington, DC, USA: The National Academy Press; 2005. (edited by: B. Fan).
    1. Phelan S., Wadden T., Berkowitz R. I., et al. Impact of weight loss on themetabolic syndrome. International Journal of Obesity. 2007;31(9):1442–1448.
    1. Janssen I., Katzmarzyk P. T., Ross R. Waist circumference and not body mass index explains obesity-related health risk. The American Journal of Clinical Nutrition. 2004;79(3):379–384.
    1. Grievink L., Alberts J. F., O'Niel J., Gerstenbluth I. Waist circumference as a measurement of obesity in the Netherlands Antilles; associations with hypertension and diabetes mellitus. European Journal of Clinical Nutrition. 2004;58(8):1159–1165. doi: 10.1038/sj.ejcn.1601944.
    1. Sjöström L., Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet. 1998;352(9123):167–172. doi: 10.1016/s0140-6736(97)11509-4.
    1. Davidson M. H., Hauptman J., DiGirolamo M., et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. The Journal of the American Medical Association. 1999;281(3):235–242. doi: 10.1001/jama.281.3.235.
    1. Lichtman S. W., Pisarska K., Berman E. R., et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. The New England Journal of Medicine. 1992;327(27):1893–1898. doi: 10.1056/nejm199212313272701.
    1. Scagliusi F. B., Polacow V. O., Artioli G. G., Benatti F. B., Lancha A. H., Jr. Selective underreporting of energy intake in women: magnitude, determinants, and effect of training. Journal of the American Dietetic Association. 2003;103(10):1306–1313. doi: 10.1016/s0002-8223(03)01074-5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe